Pulse Biosciences (NASDAQ:PLSE) Shares Cross Below Fifty Day Moving Average – Here’s Why

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $17.79 and traded as low as $16.52. Pulse Biosciences shares last traded at $17.72, with a volume of 101,693 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

Pulse Biosciences Trading Up 4.0 %

The business’s 50-day simple moving average is $17.79 and its 200 day simple moving average is $14.19. The company has a market capitalization of $1.09 billion, a P/E ratio of -21.88 and a beta of 1.74.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently added to or reduced their stakes in PLSE. Vanguard Group Inc. increased its position in shares of Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares during the period. Westside Investment Management Inc. boosted its stake in Pulse Biosciences by 97.8% during the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after buying an additional 31,440 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after acquiring an additional 9,639 shares during the period. Inspire Investing LLC raised its position in Pulse Biosciences by 32.1% in the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after acquiring an additional 10,039 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.